Refine by
Clinical Safety Articles & Analysis
209 news found
Food and Drug Administration (FDA), further reinforcing the platform’s safety, reliability, and clinical value in modern radiation oncology. According to the official SFDA authorization document, RTsafe is authorized to market its patient-specific pre-radiotherapeutic end-to-end verification devices in the Kingdom enabling comprehensive end-to-end ...
ByRTsafe
Adial announced the publication of a peer-reviewed article highlighting the promising clinical results, strong safety profile and high compliance among patients administered AD04 (low-dose ondansetron), the Company's lead investigational new drug product being developed for the treatment of Alcohol Use Disorder (AUD). The publication also reported the results of ...
(NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced the completion of patient enrollment in the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV). APEX-AV is a clinical ...
The two-year results reinforce the long-term efficacy and safety and the unprecedented durability of aflibercept 8 mg in patients with DME. ...
ByBayer AG
Lack of funding, safety issues, and patient dropouts are some of the struggles clinical development teams face. ...
Endogenous peptides with analgesic potential include endorphins via the mu receptor, dynorphins via the kappa receptor and enkephalins via the delta receptor. Kappa and delta opioid agonists have been shown to provide analgesic benefit while sparing toxic mu agonist toxicity1 . Preclinical data supports analgesia from enkephalin without significant opioid tolerance, or drug liking. Unfortunately, ...
The companies will jointly develop the compounds for the multiple system atrophy (MSA) and Parkinson’s disease (PD) indications based on early-stage clinical studies, and consider exploring additional indications based on clinical outcomes. ...
Lipella Pharmaceuticals Inc. said it saw positive top-line results from its recently completed Phase 2a clinical trial evaluating the safety and efficacy of its drug candidate LP-10 for hemorrhagic cystitis. ...
To request a meeting, please contact Cingulate Investor Relations at mkreps@darrowir.com. The Phase 3 clinical trial is an adult dose-optimization study to assess the onset and duration of efficacy along with the safety of CTx-1301 in adults with ADHD compared to placebo. ...
We performed 2 clinical trials in leading neurorehabilitation hospitals in Germany and Spain proving safety, feasibility and usability of the exoskeleton in a clinical setting, and showing significant improvements in clinical outcomes and benefits in rehabilitation. A Multicentric Clinical investigation in ...
Complementing the Explorer, they provide open access to information from a variety of areas, including clinical trials and safety studies of Bayer’s crop protection products, or its political activities. ...
ByBayer AG
Independent Data Monitoring Committee authorized proceeding to Phase 2 at highest dose level tested following review of clinical safety data from the Phase 1 dose escalation Phase 2 clinical data readouts on safety and efficacy of XC001 anticipated in 2022 Company plans to commence study startup of XC001 as an adjunct to CABG ...
It is also the only device producing an IAEA-compliant BNCT beam for the effective and safe clinical use of neutrons. During the commissioning process, the Helsinki nuBeam® device has demonstrated both robustness and reliable operation, validating Neutron Therapeutics’ technology as the best choice for high-throughput BNCT clinics with stringent ...
About the TORCH-2 Trial The TORCH-2 trial (NCT04337463) was designed to evaluate the safety and efficacy of ATG-008 combined with toripalimab (PD-1 antibody) in subjects with advanced solid tumors. ...
Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, is pleased to announce the commencement of an Investigational New Drug (IND) enabling safety study with its novel XF-73 Dermal formulation. ...
Elizabeth Holt, Head of Global Medical, Clinical, and Safety, LifeScan. “These data suggest the potential benefits of integrating easy to use tools into patients’ day-to-day routines that give them an understanding of what their blood glucose numbers mean, actions they can take, and the encouragement to help them stay on ...
ByLifeScan
” Over the last two decades, disease activity in rheumatoid arthritis (RA) has improved, yet fatigue and pain continue to hinder patients’ quality of life (QOL), and ability to function.2,3 Less than 30% of patients are satisfied with their pain levels and 40-80% of RA patients are affected by fatigue.4,5 Pain and fatigue have negative impacts on mental and physical QOL, including ...
In addition to their outstanding clinical research in oncology, Peter Mac through Cell Therapies Pty Ltd has substantial experience in manufacturing of cell therapies for cancer.” The key aspects of the collaborative research are setting up clinical-scale manufacturing of CTH-001 and conducting a Phase I clinical trial. This will initially ...
BOC Sciences, as a professional contract research organization, can take care of the PROTAC in vivo evaluation workload for clients with a transparent project process and comprehensive evaluation reports to facilitate their PROTAC discovery and development programs prior to clinical trials. According to the classification of drugs and the characteristics of pharmacological ...
Gesynta Pharma AB today announces the decision to advance the development of its clinical-stage drug candidate GS-248 in endometriosis - a chronic inflammatory condition affecting approximately 10 percent of all women of reproductive age. ...